Header Logo

Connection

Lynn Morris to RNA, Viral

This is a "connection" page, showing publications Lynn Morris has written about RNA, Viral.
Connection Strength

1,604
  1. Genotypic and phenotypic characterization of viral isolates from HIV-1 subtype C-infected children with slow and rapid disease progression. AIDS Res Hum Retroviruses. 2006 May; 22(5):458-65.
    View in: PubMed
    Score: 0,237
  2. Human immunodeficiency virus-1 RNA levels and CD4 lymphocyte counts, during treatment for active tuberculosis, in South African patients. J Infect Dis. 2003 Jun 15; 187(12):1967-71.
    View in: PubMed
    Score: 0,194
  3. Evidence for both Intermittent and Persistent Compartmentalization of HIV-1 in the Female Genital Tract. J Virol. 2019 05 15; 93(10).
    View in: PubMed
    Score: 0,146
  4. HIV Superinfection Drives De Novo Antibody Responses and Not Neutralization Breadth. Cell Host Microbe. 2018 10 10; 24(4):593-599.e3.
    View in: PubMed
    Score: 0,140
  5. High human immunodeficiency virus type 1 RNA load in the cerebrospinal fluid from patients with lymphocytic meningitis. J Infect Dis. 1998 Feb; 177(2):473-6.
    View in: PubMed
    Score: 0,134
  6. Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies. Nat Med. 2015 Nov; 21(11):1332-6.
    View in: PubMed
    Score: 0,114
  7. Drug resistance among newly diagnosed HIV-infected children in the era of more efficacious antiretroviral prophylaxis. AIDS. 2014 Jul 17; 28(11):1673-8.
    View in: PubMed
    Score: 0,105
  8. Durable HIV RNA resuppression after virologic failure while remaining on a first-line regimen: a cohort study. Trop Med Int Health. 2014 Feb; 19(2):236-9.
    View in: PubMed
    Score: 0,102
  9. Silencing of HIV-1 subtype C primary isolates by expressed small hairpin RNAs targeted to gag. AIDS Res Hum Retroviruses. 2006 May; 22(5):401-10.
    View in: PubMed
    Score: 0,059
  10. Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission. AIDS. 2006 Apr 24; 20(7):995-1002.
    View in: PubMed
    Score: 0,059
  11. Characterization of human immunodeficiency virus type 1 from a previously unexplored region of South Africa with a high HIV prevalence. AIDS Res Hum Retroviruses. 2005 Jan; 21(1):103-9.
    View in: PubMed
    Score: 0,054
  12. Provincial and national prevalence estimates of transmitted HIV-1 drug resistance in South Africa measured using two WHO-recommended methods. Antivir Ther. 2019; 24(3):203-210.
    View in: PubMed
    Score: 0,036
  13. Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses. Cell Host Microbe. 2015 Sep 09; 18(3):354-62.
    View in: PubMed
    Score: 0,028
  14. Viral suppression following switch to second-line antiretroviral therapy: associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch. J Infect Dis. 2014 Mar 01; 209(5):711-20.
    View in: PubMed
    Score: 0,025
  15. Genotypic resistance at viral rebound among patients who received lopinavir/ritonavir-based or efavirenz-based first antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr. 2011 Nov 01; 58(3):304-8.
    View in: PubMed
    Score: 0,022
  16. HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine. AIDS. 2011 Jul 31; 25(12):1461-9.
    View in: PubMed
    Score: 0,021
  17. Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa. AIDS Res Hum Retroviruses. 2011 Sep; 27(9):945-56.
    View in: PubMed
    Score: 0,021
  18. Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial. JAMA. 2010 Sep 08; 304(10):1082-90.
    View in: PubMed
    Score: 0,020
  19. Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. Clin Infect Dis. 2009 Dec 15; 49(12):1928-35.
    View in: PubMed
    Score: 0,019
  20. Optimization of allele-specific PCR using patient-specific HIV consensus sequences for primer design. J Virol Methods. 2010 Mar; 164(1-2):122-6.
    View in: PubMed
    Score: 0,019
  21. Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog. 2009 Sep; 5(9):e1000598.
    View in: PubMed
    Score: 0,019
  22. Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodies. Virology. 2007 Nov 10; 368(1):172-81.
    View in: PubMed
    Score: 0,016
  23. Viral dynamics and CD4+ T cell counts in subtype C human immunodeficiency virus type 1-infected individuals from southern Africa. AIDS Res Hum Retroviruses. 2005 Apr; 21(4):285-91.
    View in: PubMed
    Score: 0,014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.